Atlas Trials

Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer

Clinical trial NCT05726175 · UNKNOWN

Trial details

NCT number
NCT05726175
Sponsor
West China Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Breast Cancer
Start date
2023-03-01
Primary completion
2024-07-31
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.